Update shared on19 Aug 2025
Fair value Increased 20%The notable upward revision in Biovica International’s fair value reflects a sharp reduction in its future P/E ratio, with the consensus analyst price target rising from SEK1.50 to SEK1.80.
What's in the News
- Completed SEK 80 million rights offering with A and B shares at SEK 0.63 each, including attached warrants; anchor investors subject to a 6-month lock-up post-offering.
- Launched DiviTum TKa as an LDT for early breast cancer in the US, expanding the addressable market fivefold to approximately USD 3 billion annually; test supported by clinical data and covered by Medicare pricing.
- Secured new and expanded contracts with Tier-1 pharma clients, adding work orders totaling over SEK 5 million and signing a master service agreement with a leading US biopharma for Phase 1 CDK4/6 inhibitor trials.
- EPO granted new patent for TKa biomarker in immuno-oncology, covering prediction of immune checkpoint inhibitor efficacy.
- Raised guidance for net sales: SEK 8.5 million for FY25, SEK 50 million for FY26, and SEK 150 million for FY27.
Valuation Changes
Summary of Valuation Changes for Biovica International
- The Consensus Analyst Price Target has significantly risen from SEK1.50 to SEK1.80.
- The Future P/E for Biovica International has significantly fallen from 9.19x to 4.77x.
- The Net Profit Margin for Biovica International remained effectively unchanged, at 21.33%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.